Figure 4.
EFS for patients with ITDpos treated on arm C of AAML1031 with sorafenib and HCT in CR1 according to cooccurring risk groups (FR, INT, and PR) and those with PR mutations further stratified according to presence of NUP98-NSD1 fusion.
EFS for patients with ITDpos treated on arm C of AAML1031 with sorafenib and HCT in CR1 according to cooccurring risk groups (FR, INT, and PR) and those with PR mutations further stratified according to presence of NUP98-NSD1 fusion.
